Mesa Laboratories (NASDAQ:MLAB) Hits New 12-Month High – Here’s Why

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $115.52 and last traded at $114.1010, with a volume of 49600 shares changing hands. The stock had previously closed at $112.80.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a report on Tuesday. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $94.00.

Mesa Laboratories Stock Performance

The stock has a market cap of $630.35 million, a P/E ratio of 133.89 and a beta of 0.92. The stock has a fifty day simple moving average of $100.51 and a 200-day simple moving average of $95.69. The company has a quick ratio of 1.29, a current ratio of 1.72 and a debt-to-equity ratio of 0.78.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 EPS for the quarter. The company had revenue of $60.14 million during the quarter. Mesa Laboratories had a return on equity of 22.87% and a net margin of 1.92%.

Mesa Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 31st. Mesa Laboratories’s dividend payout ratio is presently 53.33%.

Insiders Place Their Bets

In other news, SVP Brian David Archbold sold 2,516 shares of Mesa Laboratories stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $225,182.00. Following the transaction, the senior vice president directly owned 6,377 shares of the company’s stock, valued at $570,741.50. This trade represents a 28.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO John Sakys sold 2,827 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $253,016.50. Following the completion of the transaction, the chief financial officer directly owned 19,785 shares of the company’s stock, valued at $1,770,757.50. This trade represents a 12.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 8,277 shares of company stock worth $770,122. Company insiders own 2.80% of the company’s stock.

Institutional Investors Weigh In On Mesa Laboratories

Several large investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. raised its position in shares of Mesa Laboratories by 5,366.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 322 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Mesa Laboratories in the 4th quarter valued at approximately $27,000. Kestra Advisory Services LLC bought a new stake in Mesa Laboratories during the 4th quarter worth approximately $55,000. BNP Paribas Financial Markets increased its stake in Mesa Laboratories by 30.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock worth $69,000 after purchasing an additional 243 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after buying an additional 684 shares during the period. 90.60% of the stock is currently owned by institutional investors.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.